JP2024515830A5 - - Google Patents
Info
- Publication number
- JP2024515830A5 JP2024515830A5 JP2023566515A JP2023566515A JP2024515830A5 JP 2024515830 A5 JP2024515830 A5 JP 2024515830A5 JP 2023566515 A JP2023566515 A JP 2023566515A JP 2023566515 A JP2023566515 A JP 2023566515A JP 2024515830 A5 JP2024515830 A5 JP 2024515830A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163181807P | 2021-04-29 | 2021-04-29 | |
| US63/181,807 | 2021-04-29 | ||
| PCT/US2022/026908 WO2022232494A1 (en) | 2021-04-29 | 2022-04-29 | Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024515830A JP2024515830A (ja) | 2024-04-10 |
| JP2024515830A5 true JP2024515830A5 (https=) | 2025-05-09 |
| JPWO2022232494A5 JPWO2022232494A5 (https=) | 2025-05-09 |
Family
ID=81748326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023566515A Pending JP2024515830A (ja) | 2021-04-29 | 2022-04-29 | 母乳を出している女性における大うつ病性障害および産後うつ病の処置における使用のための神経活性ステロイド |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240216396A1 (https=) |
| EP (1) | EP4329769A1 (https=) |
| JP (1) | JP2024515830A (https=) |
| CN (1) | CN117580580A (https=) |
| AU (1) | AU2022267304A1 (https=) |
| CA (1) | CA3217866A1 (https=) |
| IL (1) | IL307980A (https=) |
| MX (1) | MX2023012728A (https=) |
| WO (1) | WO2022232494A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2015002252A (es) | 2012-08-21 | 2015-07-21 | Sage Therapeutics Inc | Metodos para tratar epilepsia o estado de epilepsia. |
| JP6470258B2 (ja) | 2013-04-17 | 2019-02-13 | セージ セラピューティクス， インコーポレイテッド | １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| TWI904593B (zh) | 2016-08-23 | 2025-11-11 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| EP3720867A1 (en) | 2017-12-08 | 2020-10-14 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6470258B2 (ja) | 2013-04-17 | 2019-02-13 | セージ セラピューティクス， インコーポレイテッド | １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| TWI904593B (zh) | 2016-08-23 | 2025-11-11 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| EP3678670A1 (en) * | 2017-09-07 | 2020-07-15 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| CA3103421A1 (en) * | 2018-06-12 | 2019-12-19 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
| CN113939298A (zh) * | 2018-12-14 | 2022-01-14 | 普拉西斯精密医药公司 | 用于治疗抑郁症的方法 |
| US20230285417A1 (en) | 2020-07-20 | 2023-09-14 | Sage Therapeutics, Inc. | Formulations of 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
-
2022
- 2022-04-29 US US18/557,705 patent/US20240216396A1/en active Pending
- 2022-04-29 CN CN202280045723.6A patent/CN117580580A/zh active Pending
- 2022-04-29 AU AU2022267304A patent/AU2022267304A1/en active Pending
- 2022-04-29 CA CA3217866A patent/CA3217866A1/en active Pending
- 2022-04-29 JP JP2023566515A patent/JP2024515830A/ja active Pending
- 2022-04-29 MX MX2023012728A patent/MX2023012728A/es unknown
- 2022-04-29 IL IL307980A patent/IL307980A/en unknown
- 2022-04-29 EP EP22724194.0A patent/EP4329769A1/en active Pending
- 2022-04-29 WO PCT/US2022/026908 patent/WO2022232494A1/en not_active Ceased